Equities

Shanghai Fudan Forward S&T Co Ltd

600624:SHH

Shanghai Fudan Forward S&T Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.57
  • Today's Change0.09 / 2.01%
  • Shares traded5.53m
  • 1 Year change-27.46%
  • Beta0.9722
Data delayed at least 15 minutes, as of Mar 28 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.

  • Revenue in CNY (TTM)730.70m
  • Net income in CNY-18.88m
  • Incorporated1990
  • Employees1.43k
  • Location
    Shanghai Fudan Forward S&T Co LtdNo. 525, Guoquan RoadSHANGHAI 200433ChinaCHN
  • Phone+86 2 163872288
  • Fax+86 2 163869700
  • Websitehttp://www.forwardgroup.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ningbo Menovo Pharmaceutical Co Ltd1.15bn179.28m2.97bn2.30k18.331.38--2.570.760.764.8410.090.25191.133.90502,754.304.206.366.4510.2332.1236.3516.6916.050.9153--0.408312.6415.8019.20137.6749.9545.988.97
Henan Taloph Pharmaceutical Stock Co Ltd2.11bn-32.19m2.98bn2.66k--2.00--1.42-0.0568-0.05683.742.590.61223.842.39792,445.10-1.07-0.7076-2.13-1.2525.0629.08-1.76-1.530.80440.23330.3233--22.2010.91-1,303.26--8.48--
Shanghai ZJ Bio-Tech Co Ltd648.65m166.57m3.02bn435.0017.960.7468--4.660.86450.86453.3420.800.14580.62382.671,491,159.003.7425.684.1129.1056.9063.3925.6837.2713.78--0.001531.5015.2364.570.230571.3121.08--
Shanghai Fudan Forward S&T Co Ltd730.70m-18.88m3.07bn1.43k--3.53--4.20-0.0278-0.02781.081.270.39430.67668.37512,413.10-0.8747-0.4088-1.49-0.720439.1945.22-2.22-0.86110.5840.37010.3741---24.231.4196.58---3.22--
Data as of Mar 28 2024. Currency figures normalised to Shanghai Fudan Forward S&T Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.17%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 29 Feb 2024677.45k0.10%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023452.63k0.07%
China Universal Asset Management Co., Ltd.as of 30 Jun 202338.00k0.01%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20230.000.00%
GF Fund Management Co., Ltd.as of 30 Jun 20230.000.00%
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.